FinscoFinsco

Anika Therapeutics (US.ANIK)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ANIK · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion152.1%↓
ROE-1.3%↑
Cash Conversion-→
D/E Ratio0.18↓
Gross Margin64.7%↑
US.ANIK (Anika Therapeutics) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   152.1%    ↓
ROE               -1.3%    ↑
Cash Conversion       -    →
D/E Ratio          0.18    ↓
Gross Margin      64.7%    ↑
Key Metrics
US.ANIK (Anika Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 152.1% ↓
ROE -1.3% ↑
Cash Conversion - →
D/E Ratio 0.18 ↓
Gross Margin 64.7% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies